Psychiatric Services
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Psychiatr Serv 60:125-a-126, January 2009
doi: 10.1176/appi.ps.60.1.125-a
© 2009 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Davis, J. M.
* Articles by Glick, I. D.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Davis, J. M.
* Articles by Glick, I. D.
Related Collections
* Veterans
* Skills Training
* Cognitive Therapy

Letter

CATIE Findings Revisited

To the Editor: We applaud the special section in the May 2008 issue with commentaries interpreting findings from the landmark Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study (1,2). The introduction stated that "the literature suggests little evidence that, with the exception of clozapine, second-generation antipsychotics confer superior efficacy in ameliorating positive and negative symptoms and improving cognition or that they are more tolerable." Our meta-analysis (3) is one of ten published reports cited at the end of this statement.

For the record, like the animals in Animal Farm, some second-generation antipsychotics—olanzapine, risperidone, and amisulpride—were shown in our analysis to be superior to first-generation antipsychotics. In addition, the report by Lieberman and colleagues (4) of results from phase I of CATIE showed that olanzapine was superior in efficacy to the first-generation antipsychotic perphenazine. We agree that clozapine is more effective than first-generation antipsychotics and that given the data currently available, the other second-generation antipsychotics—quetiapine, ziprasidone, and aripiprazole—have not been shown to have better efficacy than first-generation agents.

John M. Davis, M.D., Stefan Leucht, M.D. and Ira D. Glick, M.D.


  References

 
TOP
 References
 

  1. Swartz MS: Introduction to the CATIE special section. Psychiatric Services 59:497–499,2008.[Free Full Text]
  2. Swartz MS, Stroup TS, McEvoy JP, et al: What CATIE found: results from the schizophrenia trial. Psychiatric Services 59:500–506,2008[Abstract/Free Full Text]
  3. Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 60:553–564,2003.[Abstract/Free Full Text]
  4. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. NEJM 353:1209–1223,2005[Abstract/Free Full Text]




This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Davis, J. M.
* Articles by Glick, I. D.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Davis, J. M.
* Articles by Glick, I. D.
Related Collections
* Veterans
* Skills Training
* Cognitive Therapy

Get information about faster international access.

Privacy Policy

Copyright © 2009 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org